STEAP4 regulates focal adhesion kinase activation and CpG motifs within STEAP4 promoter region are frequently methylated in DU145, human androgen-independent prostate cancer cells

Author(s)
Tamura, Takahiko; Chiba, Joe

Citation
International Journal of Molecular Medicine, 24(5), pp.599-604; 2009

URL
http://hdl.handle.net/10069/24039
STEAP4 regulates focal adhesion kinase activation and CpG motifs within STEAP4 promoter region are frequently methylated in DU145, human androgen-independent prostate cancer cells

TAKAHIKO TAMURA1,2 and JOE CHIBA1

1Department of Biological Science and Technology, Tokyo University of Science, 2641 Yamazaki, Noda-shi, Chiba 278-8510, Japan

Received June 19, 2009; Accepted July 22, 2009

DOI: 10.3892/ijmm_00000270

Abstract. The possible roles of STEAP4 in cancer progression have not been reported. In this study, we report that STEAP4 expression is able to inhibit anchorage-independent cell growth. We also demonstrate that STEAP4 associates with focal adhesion kinase (FAK) and regulate the activity of FAK through Y397 phosphorylation. Furthermore, we show that CpG sequences in STEAP4 promoter region were frequently methylated in DU145, androgen-independent prostate cancer cells. Demethylation treatment induced STEAP4 expression in DU145, suggesting the possibility that STEAP4 expression in cancer cells is in part epigenetically regulated. Collectively, these data demonstrate a novel function of STEAP4 and that STEAP4 may play an important role in tumor malignancy.

Introduction

STEAP4 (six transmembrane epithelial antigen of the prostate 4) is a member of the STEAP family (1). Structurally, STEAP4 (also called STAMP2) is a 459 amino acid protein characterized by a molecular topology of six transmembrane domains. The cytoplasmic N-terminal domain of STEAP4 shows structural similarity with bacterial and archaeal FNO oxidoreductase and STEAP4 exhibits a strong iron reductase activity (2). The analysis of STEAP4 deficient mice shows that STEAP4 controls inflammatory response in adipocytes and loss of STEAP4 leads to a metabolic syndrome (3). STEAP4 is broadly expressed in various normal tissues including placenta, lung, heart, prostate and adipose (1,4). However, in contrast to STEAP1 whose expression is widely detected in many cancers (e.g. prostate, lung, bladder, pancreas, ovary, colon) (5,6), a previous report demonstrated that many human cancer cells do not express STEAP4, although LNCaP, human androgen-dependent prostate cancer cells express STEAP4 (1). This may suggest that STEAP4 expression is deleterious in cancer progression but it remained unclear. In addition, the mechanisms of down-regulation of STEAP4 expression in cancer cells have not been studied. Such research may elucidate a new approach to tumor malignancy and develop anti-tumor therapeutic strategy targeted to expression and function of STEAP4. Actually, we previously developed a dendritic cell-mediated immunization protocol and generated monoclonal antibodies against external portions of STEAP4 (7).

In this study, we investigated the possible roles of STEAP4 in cancer progression. Unexpectedly, we found that STEAP4 expression may inhibit anchorage-independent cell growth. This phenomenon may be mediated by the regulation of phospho-Y397 of focal adhesion kinase (FAK) by STEAP4. Furthermore, we found that CpG sequences in STEAP4 promoter region were frequently methylated in androgen-independent prostate cancer cells (DU145), but not in androgen-dependent prostate cancer cells (LNCaP). Demethylation treatment such as 5-aza-2-deoxycytidine or 5-aza-cytidine induced STEAP4 expression in DU145, suggesting the possibility that STEAP4 expression in more aggressive prostate cancer cells is in part epigenetically regulated by CpG methylation-mediated mechanism. Our results indicate a novel function of STEAP4 and provide evidence that STEAP4 may be involved in tumor malignancy.

Materials and methods

Cells. 293T cells were maintained in Dulbecco's modified Eagle's medium (DMEM) supplemented with 10% heat-inactivated fetal calf serum (FCS). For construction of 293T cells stably expressing STEAP4, we used Flp-In system
crylate (poly-HEMA)-coated dishes, 1x10^6 cells were plated. The experiment was repeated twice. As >20 cells. Samples were assayed in triplicates and the resulting colonies were counted with a colony being defined (4F2) was added in both of upper and lower agar layers. The layer of 0.5% agar in DMEM 10% FCS, and then cultured for 14 days. In some cases, 60 μg/ml anti-STEAP4 mAb was used as secondary antibody.

**Immunofluorescence staining.** The staining procedure was described previously (7). As primary antibody for anti-STEAP4 staining, 4F2 mAb was used. The FITC-conjugated anti-mouse IgG (Jackson Immunoresearch, West Grove, PA) was used as secondary antibody.

**Construction of the expression plasmid for STEAP4-GFP fusion protein.** STEAP4-GFP fusion construct was generated by in frame ligation of C-terminal of STEAP4 and N-terminal of GFP for which cDNAs were produced by PCR. The linker sequence between STEAP4 and GFP has a KpnI site. The primer sequences for STEAP4 with KpnI linker were 5’-GACCCACCATGGGAGAAGGTTGATAGA-3’ and 5’-TCGGTTACCTGTATTGGTTGTCTCTTIC-3’. The primer sequences for GFP with KpnI linker were 5’-GAG GTACCATGTGGAGCCAGGAG-3’ and 5’-GACCTT TTGTACAGCTCGTC-3’. The sequences of PCR products were confirmed by standard sequencing method using ABI PRISM 3100-Avant DNA sequencer (Applied Biosystems, Foster City, CA). The DNA fragment encoding STEAP4-GFP fusion protein was inserted into pCAGGS, resulting in pcAGGS-STEAP4-GFP. The STEAP4-GFP protein in transfected 293T cells showed the same subcellular localization as the intact STEAP4 (data not shown).

**Anchorage-independent cell culture.** For soft agar colony formation assays, cells (4x10^5) were suspended in 0.33% agar in DMEM 10% FCS, poured onto plates containing a layer of 0.5% agar in DMEM 10% FCS, and then cultured for 14 days. In some cases, 60 μg/ml anti-STEAP4 mAb (4F2) was added in both of upper and lower agar layers. The resulting colonies were counted with a colony being defined as >20 cells. Samples were assayed in triplicates and the experiment was repeated twice.

For suspension culture on poly-2-hydroxyethylmethacrylate (poly-HEMA)-coated dishes, 1x10^6 cells were plated into 60 mm poly-HEMA- (Sigma, St. Louis, MO) coated dishes. The poly-HEMA-coated dishes were prepared by applying 2 ml of poly-HEMA solution (12 mg/ml in 95% ethanol) onto the dishes, drying in tissue culture hood, applying 2 ml of poly-HEMA solution (12 mg/ml in 95% ethanol) onto the dishes, drying in tissue culture hood, followed by wash with PBS.

**Western blotting analysis.** The proteins in cell lysates were separated by SDS-PAGE and transferred to Immobilon membranes (Millipore, Bedford, MA). The Block-Ace (Snow Brand Milk Products, Tokyo, Japan) solution was used for blocking the membranes, and membranes were then reacted with 1:250 diluted anti-FAK (phosphoY397; Becton-Dickinson, San Jose, CA) antibody for 1 h at room temperature. After washing, the membranes were incubated with horseradish peroxidase-conjugated goat anti-mouse IgG (Promega, Madison, WI). After washing, the membranes were immersed in ECL solution (GE healthcare, Piscataway, NJ) and intensity of reactive band was analyzed using LAS1000 system (Fujifilm, Tokyo, Japan). Then, the bound antibodies were stripped from the membrane in 2% SDS at 50˚C, and the membranes were incubated with 1:500 diluted anti-FAK (total; Becton-Dickinson) followed by the same procedure to detect phospho-Y397 FAK.

**Immunoprecipitation.** The cells were lysed in NP40 lysis buffer which consisted of 10 mM Tris-HCl (pH 7.4), 150 mM NaCl, 0.5 mM EDTA and 1% NP40 with PhosSTOP (Roche, Indianapolis, IN) and protease inhibitor cocktail set (Calbiochem, La Jolla, CA) for 15 min on ice. The cell extracts were prepared by centrifugation to remove cell debris. The cell extracts were mixed with anti-STEAP4 mAb (4F2) or anti-GFP antibody (Clontech, Palo Alto, CA) for 1 h at 4˚C and protein G-Sepharose beads (GE Healthcare) were added and incubated for another 1 h at 4˚C. After washing, beads were suspended in SDS-PAGE sample buffer and boiled to release the bound proteins, which were subject to Western blot analysis.

**Bisulfite genomic sequencing.** The genomic DNA from human prostate cancer cells was isolated using a kit (MagExtractor, Toyobo, Osaka, Japan). The sodium bisulfite treatment of genomic DNA was done according to the manufacturer’s instruction (BisulFast DNA modification kit for methylated DNA detection, Toyobo). The converted DNA was used as template for PCR. The condition of PCR was 94˚C 25 sec, 52˚C 25 sec, 72˚C 25 sec of 40 cycles using Ex Taq hot start version (Takara, Shiga, Japan). The primer sequences for region-1 was 5’-GTTTTTTTAGGAAAAGGGGATTTTT-3’ and 5’-TAAATCCCAACAACTAAAAAAA-3’. The primer sequences for region-2 was 5’-ATTTTTTTATTAGAAATAAGTTTTTTT-3’ and 5’-AAATATACCCACCTAAAAAAAAA-3’. The PCR product was subcloned into pGEM-T easy vector (Promega) and the independent plasmid clones were sequenced using ABI PRISM 3100 sequencer.

**RT-PCR.** The cells were incubated with 10 μM 5-aza-2-deoxycytidine (5-aza-dC; Sigma). This dose of 5-aza-dC showed slowing of cell proliferation but not complete cell proliferation.
death (data not shown). Next day (day 1), the medium with fresh 5-aza-dC was replaced. On day 3, total RNA was isolated using Isogen (NipponGene, Toyama, Japan). In some cases, 1 μM 5-aza-cytidine (5-aza-C; Sigma) was used. The cDNA was produced using oligo(dT) primer and Superscript II (Invitrogen). The PCR cycle was 94˚C 30 sec, 50˚C 30 sec, 72˚C 30 sec (35 cycles for STEAP4, 25 cycles for GAPDH). The primer sequences for STEAP4 were 5'-ACACAGAACACACGCTCCTT-3' and 5'-TGACGGACTATGAGCCAGGA-3'. The primer sequences for GAPDH were 5'-GAGCTGGCGGGAAGCTCAC-3' and 5'-TGTCATACCAGGAAATGAGC-3'.

Results

STEAP4 decreases soft agar colony formation. To explore possible function of STEAP4, 293T cells stably expressing STEAP4 (293T-STEAP4) were constructed. The immunostaining analysis showed that the expression of STEAP4 was mainly detected in cell surface of 293T-STEAP4 cells, although 293T-empty cells, in which empty vector was stably transfected, were not significantly stained (Fig. 1). The proliferation of 293T-STEAP4 cells was the same as the 293T-empty cells under adherent culture condition (data not shown). However, in soft agar colony formation assay, the number of colonies in 293T-STEAP4 cells was significantly decreased compared with the 293T-empty (Fig. 2). The inhibition of colony formation in 293T-STEAP4 was reversed by anti-STEAP4 monoclonal antibody (Fig. 2). Collectively, STEAP4 was able to inhibit anchorage-independent cell proliferation.

STEAP4 regulates Y397 phosphorylation of FAK. The anchorage-independent cell growth is one of the most prominent features of cellular malignancy. The molecular mechanism of anchorage-independent cell growth is not fully understood, but previous studies suggest that FAK plays a critical role and phosphorylation of Y397 is important (8,9). Therefore, we investigated the activation status of FAK in the presence of STEAP4. The culture of 293T cells in poly-HEMA-coated dishes for 24 h resulted in >90% trypan blue negative and 293T cells are likely to be resistant to anoikis, although prolonged culture (e.g. 10 days) resulted in cell death. When 293T-empty cells were non-adherently cultured in poly-HEMA-coated dishes, Y397 phosphorylation of FAK was time-dependently increased (Fig. 3A). Such increase of Y397 phosphorylation in suspension culture condition of cancer cells was reported previously (10,11). In contrast, Y397 phosphorylation of FAK in 293T-STEAP4 cells was not increased, but rather decreased in suspension culture (Fig. 3A). The anti-STEAP4 antibody enhanced Y397 phosphorylation in 293T-STEAP4 cells, although did not change in 293T-empty cells (Fig. 3B). Collectively, STEAP4
could suppress Y397 phosphorylation of FAK in suspension culture condition, suggesting that this insufficient activation of FAK in suspension may explain inhibition of soft agar colony formation of SETAP4 expressing cells. STEAP4 associates with FAK. The subcellular localization of STEAP4 protein is mainly plasma membrane and similar to FAK. To determine whether STEAP4 physically interacts with FAK, the extracts of 293T-STEAP4 cells were immunoprecipitated with anti-STEAP4 antibody and reacted with anti-FAK antibody for Western blot analysis. In Fig. 4A, FAK was shown co-immunoprecipitated with STEAP4, suggesting that STEAP4 interacts with FAK in 293T-STEAP4 cells. The molecular weight of STEAP4 (approximately 52 kDa) is almost same as IgG heavy chain and hard to discriminate in immunoprecipitation. Therefore, it was uncertain whether the anti-STEAP4 antibody was actually able to immunoprecipitate STEAP4 protein. Thus, we used an expression construct for STEAP4-GFP fusion protein. Because GFP is fused to C-terminal of STEAP4, STEAP4-GFP is sized up in molecular weight and easy to discriminate with IgG heavy chain. Indeed, anti-STEAP4 mAb was used for immunoprecipitation analysis because STEAP4-GFP fusion protein was clearly detected in immunoprecipitation using anti-STEAP4 mAb in 293T cells transfected with pCAGGS-STEAP4-GFP (Fig. 4A). Moreover, immunoprecipitation experiments using anti-GFP antibody demonstrated that STEAP4-GFP also associated with FAK (Fig. 4B). These results suggest that STEAP4 interacts with FAK and this association may be important to regulation of FAK function by STEAP4.

The expression of STEAP4 is down-regulated by CpG methylation mechanism in human androgen-independent prostate cancer cells. In general, less aggressive prostate cancer cells grow androgen-dependently, but more aggressive prostate cancer cells turned androgen-independent. Previous studies suggested that STEAP4 expression is detected in LNCaP, androgen-dependent, but not detected in DU145, more aggressive and androgen-independent (1). Expression of many genes in cancer cells are regulated by epigenetic mechanism including CpG methylation (12,13). Our results suggest that STEAP4 decreased anchorage-independent cell growth. Therefore, we decided to explore the possibility that STEAP4 expression might be down-regulated by CpG methylation in the course of more aggressive cancer.

As previously reported, STEAP4 mRNA expression was detected in human normal prostate and LNCaP, but not detected in DU145 (Fig. 5A). However, when DU145 cells were cultured in the presence of 5-aza-dC, demethylation reagent, STEAP4 expression in 5-aza-dC-treated DU145 cells was significantly increased in RT-PCR analysis (Fig. 5A). Furthermore, 5-aza-C, another demethylation reagent treatment gave a similar result in DU145 cells (Fig. 5A). In addition to mRNA expression level, immunofluorescence staining demonstrated increased STEAP4 expression in protein level by 5-aza-C treatment in DU145 (Fig. 5B). These results suggest that STEAP4 expression may be regulated by CpG methylation in DU145 cells.

CpG motifs within STEAP4 promoter region is frequently methylated in human androgen-independent prostate cancer cells. The analysis of genomic DNA sequence of STEAP4 gene locus (7q21.12) revealed that single-predicted CpG island exists around STEAP4 promoter region, encompassing 5’ upstream sequence and part of first exon (Fig. 6A). This prompted us to investigate CpG methylation status in LNCaP and DU145 cells. The sequence analysis of bisulfite-treated genomic DNA demonstrated that almost no CpG methylation in STEAP4 promoter region was detected in LNCaP and DU145 cells. The sequence analysis of bisulfite-treated genomic DNA demonstrated that almost no CpG methylation in STEAP4 promoter region was detected in LNCaP and DU145 cells, but methylated CpG motifs were actually found in DU145 cells (Fig. 6B). The degree of methylation seemed to be higher in region-1, which is located in 5’ upstream sequence, than region-2. These results suggest that CpG sequences in STEAP4 promoter region are frequently methylated, which may suppress STEAP4 expression in prostate cancer cells.
In this study, we investigated the possible roles of STEAP4 in cancer progression. Our results suggest that STEAP4 binds to FAK and regulates activation of FAK, which may affect the cell growth in soft agar. Moreover, our results demonstrate that methylation of CpG motifs in STEAP4 promoter region may down-regulate STEAP4 expression. Taken together, these data implicate a novel activity of STEAP4 in cancer progression.

The functions of FAK in cancer cells are diverse such as metastasis, invasion in addition to anchorage-independent proliferation. STEAP4 may modulate these properties of cancer cells through regulation of FAK activation. The many molecules relevant to FAK are known such as Src, PI-3K p85 subunit, Grb2, p130cas and paxillin. The mechanisms how STEAP4 regulates downstream signaling from Y397 phosphorylation of FAK remains to be elucidated. A previous report demonstrated that clonogenic proliferation was enhanced when STEAP4 gene was transduced, although the exact mechanism of STEAP4 activity remained unclear (1). This observation is inconsistent with our finding, but the difference of experimental condition (e.g. adherent or anchorage-independent) should be considered. We found Y397 phosphorylation of FAK in 293T-STEAP4 tends to be higher than in 293T-empty under adherent culture conditions (data not shown), which may be advantageous in clonogenic proliferation under anchorage-dependent culture condition.

Several binding proteins to STEAP3 (also called TSAP6), belonging to STEAP family, like STEAP4, were identified using yeast two-hybrid system, suggesting that STEAP3 played a role in regulation of cell proliferation (14). In this study, we showed STEAP4 binds to FAK. Moreover, the prediction software analysis (NetPhosK; http://www.cbs.dtu.dk/services/NetPhosK/) demonstrates that human

---

**Figure 5.** The demethylation treatment induced STEAP4 expression in DU145 cells. (A) RT-PCR analysis of STEAP4 expression in human prostate cancer cells. (B) Immunofluorescence staining of 5-aza-C-treated DU145 cells. For STEAP4 staining, anti-STEAP4 mAb (4F2) was used. As negative control, anti-OVA mAb was used. Scale bar = 20 μm.

**Figure 6.** CpG methylation in STEAP4 promoter region in DU145 cells. (A) The schematic depiction of CpG island in STEAP4 promoter region. The predicted CpG island and regions analyzed for bisulfite genomic sequencing are indicated. For prediction of CpG island, CpG Island Searcher (http://cpgislands.usc.edu/) was used. The position of predicted transcription start site is 1200. The vertical bars are CpG motifs. (B) The methylation status of CpG motifs in region-1 and region-2 in LNCaP and DU145 cells. The percentage of methylated CpG was calculated. Open circle: unmethylated CpG. Closed circle: methylated CpG.
STEAP4 has several putative phosphorylation sites including Src, p38 MAP kinase, GSK3 etc. This suggests that STEAP4 may be a target for post-transcriptional modification such as phosphorylation. A more detailed molecular interplay between STEAP4 and other proteins needs to be understood for STEAP4 function in cancer cells.

Our study demonstrated that CpG methylation was actually detected in STEAP4 promoter region and demethylation treatment induced STEAP4 expression in DU145 cells. However, the CpG methylation status analysis of the clinical tumor samples with various stages including prostate cancer is necessary for the comprehensive understanding of the significance of CpG methylation in STEAP4 promoter region in cancer progression. CpG methylation as a sole mechanism in down-regulation of STEAP4 in prostate cancer cells is unlikely. In this study, CpG methylation was analyzed, but other epigenetic mechanism such as histone modification also should be considered. It may be probable that expression of transcription factors that could be involved in STEAP4 expression are epigenetically regulated although the STEAP4 promoter region is not epigenetically modified. The detailed regulation mechanism of STEAP4 expression in cancer cells has not been revealed yet, and various possibilities including epigenetic mechanism, which is demonstrated in this study, should be considered.

References